Loading…
← CockpitCompetitor Analysis › 2096.HK Simcere Pharmaceutical Group LimitedOpen in the cockpit ↗

Simcere Pharmaceutical Group Limited2096.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese pharmaceutical group selling branded generics and innovative drugs in oncology, CNS and anti-infection.

≈ A mid-size Chinese pharma mixing generics and specialty drugsMomentum neutral 57
Mkt cap
$3.42B
US dollars, full cap
Free float
32%
of shares outstanding
$/day
$6.85M
20-day average traded
Fwd P/E
13.5×
forward earnings
ROIC−WACC
+9.1 pp
WACC 6.7%
Hurdle
-14 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · HKDHK$10.42
1D-0.8%
1W-4.5%
1M-4.8%
3M-14.4%
6M-5.3%
YTD-12.9%
1Y-19.1%
ATR %3.6%
52w lowhigh27.5% off high

What Simcere Pharmaceutical does

Chinese pharmaceutical group selling branded generics and innovative drugs in oncology, CNS and anti-infection.

Sells to Chinese hospitals, mostly through distributors, and its older branded generics face price pressure from state bulk-buying tenders. Newer innovative drugs carry the shift in mix, and licensing deals with other drugmakers add upfront and milestone payments to product income.

In one line: A mid-size Chinese pharma mixing generics and specialty drugs.

Products and services

  • Oncology drugs
  • CNS/neurology drugs
  • Anti-infective drugs
  • Innovative biologics pipeline

Customers

  • Hospitals
  • Pharmacies in China

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded generics
  • Innovative drug pipeline

What could go right

  • New drug launches
  • Licensing deals

What could go wrong

  • Centralized drug procurement price cuts

Moat: narrow (brand, distribution). Established hospital sales network and legacy branded-generic portfolio.

Headquarters: Nanjing, China · Founded: 1995 · Employees: 7,038

Named competitors

Simcere Pharmaceutical at a glance

Size Simcere Pharmaceutical (2096.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $3.42B, the 310th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$10.42 on 18 Nov 2026.

Performance Over six months the shares fell 5.3%, against +3.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue grew 27.2% over the last twelve months (peer median +3.6%); the operating margin is 17.8% (peer median 12.2%).

Valuation It trades at 13.5× forward earnings against a peer median of 18.2× (5th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.1 points above its cost of capital (6.7% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 1052096.HK 100
Six months, rebased to 100: Simcere Pharmaceutical against the median of its 20 peers (local-currency closes).

Simcere Pharmaceutical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$9.76BHK$8.38BHK$7.19BHK$7.30BHK$7.35B
Revenue growth—+17%-1%-1%—
Gross profitHK$8.09BHK$6.84BHK$5.77BHK$5.51BHK$5.81B
EBITDAHK$2.20BHK$1.75BHK$1.31BHK$944MHK$834M
Net incomeHK$1.76BHK$1.46BHK$783MHK$790MHK$1.08B
Free cash flowHK$2.47BHK$1.84BHK$1.19B-HK$47.3MHK$1.48B
Capital expenditureHK$1.34BHK$935MHK$841MHK$1.08BHK$788M
Total debtn/aHK$1.33BHK$1.32BHK$1.67BHK$1.81B

Quarterly statements and history in the cockpit →

Simcere Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%+40%VRDNAMLXPPLPHARMA000739002262688180ARQTACUTAASVKTXSFZNWOCKPHARMA6005113320SLSXENE15132096.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Simcere Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×50×100×150×PPLPHARMA000739002262ARQTACUTAASSFZN6005113320OGN60053515132096.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Simcere Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%000739002262ARQTWOCKPHARMA2096.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Simcere Pharmaceutical is the large dot.

Simcere Pharmaceutical competitors and peer comparison

Head to head with its named competitors (2096.HK vs 3320.HK vs 1513.HK vs 600276.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Simcere Pharmaceutical 2096.HK$3.42B-5%+27%18%13.5×-3.4%
China Resources Pharmaceutical 3320.HK$3.60B-7%+8%4%5.8×-4.9%
Livzon Pharmaceutical 1513.HK$3.73B-9%-10%19%11.3×-7.0%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%

How Simcere Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Simcere Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure2096.HKPeer medianRank in peer set
1-month return-4.8%+2.9%6th lowest of 21
6-month return-5.3%+3.4%7th lowest of 20
Distance from 52-week high-27.5%-18.6%9th lowest of 21
Revenue growth (TTM)+27.2%+3.6%5th highest of 18
Operating margin17.8%12.2%6th highest of 16
Forward P/E13.5×18.2×5th cheapest of 13
Growth the price implies (Req g, 7 yrs)-3.4%-3.1%6th least demanding of 11
Growth delivered (Del g)+10.6%+4.9%3rd highest of 11
Hurdle (Req g minus delivered)-14.0 pp-6.0 pp4th least demanding of 11
ROIC minus cost of capital+9.1 pp+4.0 pp5th highest of 17
EV / EBITDA11.3×30.7×3rd cheapest of 8
Net debt / EBITDA-0.8×2.6×2nd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Shanghai Junshi Biosciences 688180.SSChina$3.48B-31%+29%-15%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%11.3×-7.0%+2.0%

Questions

Who are Simcere Pharmaceutical's main competitors?
Named competitors: China Resources Pharmaceutical (3320.HK), Livzon Pharmaceutical (1513.HK), Hengrui Medicine (600276.SS). The cockpit's measured peer set (industry) also includes Viridian Therapeutics (VRDN), Amylyx Pharmaceuticals (AMLX), Piramal Pharma (PPLPHARMA.NS), Apeloa Pharmaceutical (000739.SZ), Jiangsu Nhwa Pharmaceutical (002262.SZ), Shanghai Junshi Biosciences (688180.SS).
Is Simcere Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 13.5× against a peer median of 18.2×, 5th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Simcere Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -5.3% against +3.4% for the median peer; over one year -19.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.